Placental transfer of sulindac and its active sulfide metabolite in humans

Wayne B. Kramer, George Saade, Ching Nan Ou, Rognerud Cheryl, Dorman Karen, Mary Mayes, Kenneth J. Moise

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OJECTIVE: Our aim was to investigate whether the human placenta is permeableto sulindc or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4. to 6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were measured by high-performance liquid chromatography. RESULTS: The maternal sulfide level was significantly higher than the fetal sulfide levels, but no significant difference was noted between maternal and fetal sulindac levels. The sulfide fetal/maternal ratio was significantly lower than the sulindac fetal/maternal ratio. The sulfide/sulindac ratio was significantly higher in maternal serum versus fetal serum. The sulfide/sulindac ratio correlated with time from drug ingestion to sampling on the maternal side only. In patients studied on more than one occasion no consistent relationship between fetal sulindac, fetal sulfide, or fetal sulfide/sulindac ratio, and gestational age could be demonstrated. CONCLUSION: The placenta is permeable to sulindac but less so to its active surface metabolite. The reduction of sulindac to its active sulfide metabolite is decreased in the human fetus.

Original languageEnglish (US)
Pages (from-to)886-890
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume172
Issue number3
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Sulindac
Sulfides
Mothers
Placenta
Gestational Age
Serum
Fetus
Eating
High Pressure Liquid Chromatography
sulindac sulfide

Keywords

  • placental transfer
  • prostaglandin synthetase inhibitor
  • sulfide metabolite
  • Sulindac

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Placental transfer of sulindac and its active sulfide metabolite in humans. / Kramer, Wayne B.; Saade, George; Ou, Ching Nan; Cheryl, Rognerud; Karen, Dorman; Mayes, Mary; Moise, Kenneth J.

In: American Journal of Obstetrics and Gynecology, Vol. 172, No. 3, 1995, p. 886-890.

Research output: Contribution to journalArticle

Kramer, Wayne B. ; Saade, George ; Ou, Ching Nan ; Cheryl, Rognerud ; Karen, Dorman ; Mayes, Mary ; Moise, Kenneth J. / Placental transfer of sulindac and its active sulfide metabolite in humans. In: American Journal of Obstetrics and Gynecology. 1995 ; Vol. 172, No. 3. pp. 886-890.
@article{8562da82a93b4e1dba43beec5bb681a3,
title = "Placental transfer of sulindac and its active sulfide metabolite in humans",
abstract = "OJECTIVE: Our aim was to investigate whether the human placenta is permeableto sulindc or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4. to 6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were measured by high-performance liquid chromatography. RESULTS: The maternal sulfide level was significantly higher than the fetal sulfide levels, but no significant difference was noted between maternal and fetal sulindac levels. The sulfide fetal/maternal ratio was significantly lower than the sulindac fetal/maternal ratio. The sulfide/sulindac ratio was significantly higher in maternal serum versus fetal serum. The sulfide/sulindac ratio correlated with time from drug ingestion to sampling on the maternal side only. In patients studied on more than one occasion no consistent relationship between fetal sulindac, fetal sulfide, or fetal sulfide/sulindac ratio, and gestational age could be demonstrated. CONCLUSION: The placenta is permeable to sulindac but less so to its active surface metabolite. The reduction of sulindac to its active sulfide metabolite is decreased in the human fetus.",
keywords = "placental transfer, prostaglandin synthetase inhibitor, sulfide metabolite, Sulindac",
author = "Kramer, {Wayne B.} and George Saade and Ou, {Ching Nan} and Rognerud Cheryl and Dorman Karen and Mary Mayes and Moise, {Kenneth J.}",
year = "1995",
doi = "10.1016/0002-9378(95)90016-0",
language = "English (US)",
volume = "172",
pages = "886--890",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Placental transfer of sulindac and its active sulfide metabolite in humans

AU - Kramer, Wayne B.

AU - Saade, George

AU - Ou, Ching Nan

AU - Cheryl, Rognerud

AU - Karen, Dorman

AU - Mayes, Mary

AU - Moise, Kenneth J.

PY - 1995

Y1 - 1995

N2 - OJECTIVE: Our aim was to investigate whether the human placenta is permeableto sulindc or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4. to 6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were measured by high-performance liquid chromatography. RESULTS: The maternal sulfide level was significantly higher than the fetal sulfide levels, but no significant difference was noted between maternal and fetal sulindac levels. The sulfide fetal/maternal ratio was significantly lower than the sulindac fetal/maternal ratio. The sulfide/sulindac ratio was significantly higher in maternal serum versus fetal serum. The sulfide/sulindac ratio correlated with time from drug ingestion to sampling on the maternal side only. In patients studied on more than one occasion no consistent relationship between fetal sulindac, fetal sulfide, or fetal sulfide/sulindac ratio, and gestational age could be demonstrated. CONCLUSION: The placenta is permeable to sulindac but less so to its active surface metabolite. The reduction of sulindac to its active sulfide metabolite is decreased in the human fetus.

AB - OJECTIVE: Our aim was to investigate whether the human placenta is permeableto sulindc or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4. to 6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were measured by high-performance liquid chromatography. RESULTS: The maternal sulfide level was significantly higher than the fetal sulfide levels, but no significant difference was noted between maternal and fetal sulindac levels. The sulfide fetal/maternal ratio was significantly lower than the sulindac fetal/maternal ratio. The sulfide/sulindac ratio was significantly higher in maternal serum versus fetal serum. The sulfide/sulindac ratio correlated with time from drug ingestion to sampling on the maternal side only. In patients studied on more than one occasion no consistent relationship between fetal sulindac, fetal sulfide, or fetal sulfide/sulindac ratio, and gestational age could be demonstrated. CONCLUSION: The placenta is permeable to sulindac but less so to its active surface metabolite. The reduction of sulindac to its active sulfide metabolite is decreased in the human fetus.

KW - placental transfer

KW - prostaglandin synthetase inhibitor

KW - sulfide metabolite

KW - Sulindac

UR - http://www.scopus.com/inward/record.url?scp=0028958643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028958643&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(95)90016-0

DO - 10.1016/0002-9378(95)90016-0

M3 - Article

C2 - 7892880

AN - SCOPUS:0028958643

VL - 172

SP - 886

EP - 890

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -